SOURCE: Peregrine Pharmaceuticals

Peregrine Pharmaceuticals

September 02, 2011 09:00 ET

Peregrine to Report First Quarter Fiscal Year 2012 Financial Results Before Market on September 9, 2011

TUSTIN, CA--(Marketwire - Sep 2, 2011) - Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced that it will report financial results for the first quarter of fiscal year 2012 on September 9, 2011 before market open and will host a conference call and webcast at 11:30 AM EDT (8:30 AM PDT). Peregrine's senior management will discuss financial results for the first quarter of fiscal year ended July 31, 2011 and will review its clinical development programs.

  • To listen to the live webcast or access the archived webcast, please visit:
  • To listen to the conference call, please call (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call. A replay of the call will be available starting approximately two hours after the conclusion of the call through September 23, 2011 by calling (855) 859-2056 or (404) 537-3406 and using passcode 93521214.

Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing multiple clinical programs in cancer and hepatitis C virus infection with its lead product candidate bavituximab and novel brain cancer agent Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (, which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at

Contact Information